Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)
Ascendis Pharma A (ASND) posted Non-Current Debt of $448.5 million for Q4 2025, up 15.76% sequentially from $387.4 million in Q3 2025, and up 14.95% YoY from $390.1 million in Q4 2024.
Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025) Analysis & Trends
Ascendis Pharma A has reported Non-Current Debt for 5 years, with the latest figure at $448.5 million in Q4 2025.
- Quarterly Non-Current Debt rose 14.95% year-over-year to $448.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $448.5 million (up 14.95% YoY) and the FY2025 annual result came in at $448.5 million, up 14.95% from the prior year.
- Non-Current Debt improved to $448.5 million in Q4 2025 per ASND's latest filing, from $387.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $598.2 million in Q3 2023 and troughed at $112.1 million in Q4 2021.
- A 5-year average of $400.4 million and a median of $390.1 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 252.82% in 2022, then tumbled 54.81% in 2024.
- Over 5 years, Non-Current Debt stood at $112.1 million in 2021, then jumped by 252.82% to $395.4 million in 2022, then sank by 39.32% to $239.9 million in 2023, then jumped by 62.6% to $390.1 million in 2024, then advanced by 14.95% to $448.5 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $448.5 million, $387.4 million, and $373.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 448.45 Mn |
| Sep 30, 2025 | 387.39 Mn |
| Jun 30, 2025 | 373.76 Mn |
| Mar 31, 2025 | 375.85 Mn |
| Dec 31, 2024 | 390.12 Mn |
| Sep 30, 2024 | 372.22 Mn |
| Jun 30, 2024 | 235.89 Mn |
| Mar 31, 2024 | 249.46 Mn |
| Dec 31, 2023 | 239.93 Mn |
| Sep 30, 2023 | 598.16 Mn |
| Jun 30, 2023 | 522.00 Mn |
| Mar 31, 2023 | 515.19 Mn |
| Dec 31, 2022 | 395.40 Mn |
| Sep 30, 2022 | 537.56 Mn |
| Jun 30, 2022 | 531.53 Mn |
| Mar 31, 2022 | 521.59 Mn |
| Dec 31, 2021 | 112.07 Mn |